Heron Therapeutics' (HRTX) Price Target Raised to $54 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Price: $0.27 -12.9%
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Rating Summary:
17 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 28
Join SI Premium – FREE
BofA/Merrill Lynch maintained a Buy rating on Heron Therapeutics (NASDAQ: HRTX) and raised its price target to $54.00 (from $46.00). The change follows positive phase 2 top-line results from HTX-011.
For an analyst ratings summary and ratings history on Heron Therapeutics click here. For more ratings news on Heron Therapeutics click here.
Shares of Heron Therapeutics closed at $33.56 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Adeptus Biotechnologies Corp. (ADPT) PT Raised to $34 at BTIG
- Brookfield prices $600M senior notes at 5.65% due 2031
- Lithia Motors (LAD) PT Lowered to $409 at Citi
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
